ILMN - Illumina, Inc.
| Previous close | 284.77 |
| Open | 288.17 |
| Bid | 284.01 x 1000 |
| Ask | 288.99 x 1000 |
| Day's range | 285.49 - 291.36 |
| 52-week range | 268.62 - 380.76 |
| Volume | 863,337 |
| Avg. volume | 1,140,526 |
| Market cap | 42.067B |
| Beta (3Y monthly) | 1.20 |
| PE ratio (TTM) | 45.44 |
| EPS (TTM) | 6.30 |
| Earnings date | 21 Oct 2019 - 25 Oct 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 322.57 |
- Motley Fool
5 Top Cancer-Fighting Stocks to Buy Now
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
- Motley Fool
Here's Why Illumina Tumbled 18.7% in July
Growth stagnated in the first half of 2019. Management says it will be temporary.
- Motley Fool
5 Things Illumina's Management Just Said That You'll Really Want to Know
Are the disappointing results for Illumina a "new normal"? Not at all, according to its top executives.
- Market Realist
Here’s What Pressured Illumina Stock after Its Q2 Results
Yesterday, genome-sequencing company Illumina (ILMN) reported its second-quarter earnings results after the market closed.
- Zacks
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.
- Simply Wall St.
Does The Data Make Illumina, Inc. (NASDAQ:ILMN) An Attractive Investment?
I've been keeping an eye on Illumina, Inc. (NASDAQ:ILMN) because I'm attracted to its fundamentals. Looking at the...
Motley FoolIllumina Inc (ILMN) Q2 2019 Earnings Call Transcript
ILMN earnings call for the period ending June 30, 2019.
- Motley Fool
Illumina Hits a Speed Bump in the Second Quarter
The genomic sequencing company reported slower revenue growth because of several issues, including a delay in closing a major population genomics deal.
- Zacks
Illumina (ILMN) Beats Q2 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of 2.27% and 0.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2019
Illumina, Inc. today announced its financial results for the second quarter of fiscal year 2019.
- Investing.com
Illumina Earnings inline, Revenue Misses In Q2
Investing.com - Illumina (NASDAQ:ILMN) reported second quarter earnings that matched analysts' expectations on Monday and revenue that fell short of forecasts.
- Motley Fool
10 Biggest Medical Device Stocks
Market caps for these medical device stocks are big. Most of them have been big winners, too.
- Zacks
Illumina, GW Pharmaceuticals, Paycom, Zscaler and Square highlighted as Zacks Bull and Bear of the Day
Illumina, GW Pharmaceuticals, Paycom, Zscaler and Square highlighted as Zacks Bull and Bear of the Day
- Zacks
What to Expect from Illumina Earnings After Preliminary Results Tanked ILMN Stock
Illumina is set to report its Q2 earnings on Monday, July 29 and investors are waiting to see if there is anything that might help the stock recover from its recent fall.
- Zacks
Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?
Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.
- Zacks
Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Illumina (ILMN) closed at $298.28, marking a +1.73% move from the previous day.
- Zacks
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
What Happens If Pacific Biosciences Isn't Acquired By Illumina?
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.
- Motley Fool
Here's Why Pacific Biosciences Is Tumbling Today
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.
- Zacks
EXEL or ILMN: Which Is the Better Value Stock Right Now?
EXEL vs. ILMN: Which Stock Is the Better Value Option?
- Business Wire
Illumina Expands Genomics Accelerator to Cambridge, UK
Partners with leading European venture capital firms to build breakthrough genomics startups
- Zacks
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
Illumina (ILMN) closed the most recent trading day at $302.29, moving -0.9% from the previous trading session.
